{
    "clinical_study": {
        "@rank": "124440", 
        "arm_group": [
            {
                "arm_group_label": "5% Sildenafil Cream (SST-6006)", 
                "arm_group_type": "Experimental", 
                "description": "5% Sildenafil Cream"
            }, 
            {
                "arm_group_label": "Oral Sildenafil 50 mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Oral Sildenafil 50 mg"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate how a single dose of sildenafil cream (SST-6006) is\n      absorbed and eliminated by the body, with and without the use of a condom, compared to a\n      single oral sildenafil dose and to evaluate the safety of sildenafil cream."
        }, 
        "brief_title": "Single-Dose Relative Bioavailability Study of SST-6006, a Topical Sildenafil Cream Versus Oral Sildenafil in Healthy Male Adults", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Willing and able to sign and date the written informed consent form (ICF) before any\n             study-specific screening procedures are performed\n\n          2. Men between the ages of 18 to 55 years, inclusive\n\n          3. Body mass index (BMI = weight [kg]/height [m]2) between 18.0 to 30.0 kg/m2, inclusive\n             and body weight of at least 50 kg\n\n          4. Nonsmoker or past smoker who has been abstinent for 6 months before study Day 1\n\n          5. Have a high probability for compliance with and completion of the study, in the\n             opinion of the Principal Investigator\n\n          6. Healthy as determined by the investigator based on medical history, physical\n             examination, clinical laboratory tests, vital sign measurements, and a normal 12-lead\n             ECG\n\n          7. Resting supine systolic blood pressure between 90 and 140 mmHg and resting supine\n             diastolic blood pressure between 50 and 90 mmHg\n\n          8. Must be able to achieve a successful erection\n\n        Exclusion Criteria:\n\n          1. Presence or history of any disorder that may prevent the successful completion of the\n             study\n\n          2. Presence of any significant cardiovascular, hepatic, renal, respiratory,\n             gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic,\n             genitourinary, or psychiatric disease, or other unstable medical condition\n\n          3. Subjects with a history of myocardial infarction, stroke, or life-threatening\n             arrhythmia within 6 months prior to study Day 1, or a history of coronary disease\n             causing angina\n\n          4. Subjects with retinitis pigmentosa and subjects with sickle cell anemia or related\n             anemias, even if they feel clinically well at the time of screening.  Subjects with\n             retinitis pigmentosa will be identified by specifically asking whether they have the\n             condition, if there are visual signs and symptoms of the condition (including\n             questioning subjects as to whether they have difficulty seeing at night or in low\n             light, and if they have any visual field deficits that indicate a loss of peripheral\n             or central vision), or if there is a family history\n\n          5. Subjects with anatomical deformations of the penis such as angulation, cavernosal\n             fibrosis or Peyronie's disease\n\n          6. History of orthostatic hypotension or orthostatic hypotension present at the\n             screening visit, defined as a drop in systolic blood pressure greater than 20 mm Hg\n             and a drop in diastolic blood pressure greater than 10 mm Hg with a change in\n             position from supine to standing\n\n          7. A history of erectile dysfunction or a prostatectomy\n\n          8. Any surgical or medical condition that may interfere with the absorption,\n             distribution, metabolism, or excretion of the test article\n\n          9. Acute disease state (eg, nausea, vomiting, fever, or diarrhea) within 7 days before\n             study Day 1\n\n         10. History of drug abuse within 1 year before study Day 1\n\n         11. History of alcoholism within 1 year before study Day 1, admitted alcohol abuse, or\n             average consumption of more than 2 standard units of alcohol per day (a standard unit\n             equals 12 ounces of beer, 1\u00bd ounces of 80-proof alcohol, or 6 ounces of wine)\n\n         12. Use of any prescription drugs within 28 days before study Day 1, or over-the-counter\n             drugs, including herbal supplements (except for the occasional use of acetaminophen\n             [Tylenol] and vitamins) within 14 days before study Day 1.  If the subject takes any\n             prescription or OTC drugs at the direction of a health care provider, that provider\n             should be consulted before medications are stopped for the purposes of study\n             participation.\n\n         13. Positive serologic findings for human immunodeficiency virus antibodies (HIV),\n             hepatitis B surface antigen (HBsAg) or hepatitis C antibodies (HCV)\n\n         14. Positive findings of urine drug screen (eg, amphetamines, barbiturates,\n             benzodiazepines, cannabinoids, cocaine, methadone, and opiates) or alcohol screen\n\n         15. Participation in a clinical trial within 30 days before study Day 1\n\n         16. Consumption of any caffeine-containing products (eg, coffee, tea, chocolate, or soda)\n             or alcoholic beverages within 48 hours before study Day 1\n\n         17. Consumption of grapefruit or grapefruit-containing products within 72 hours before\n             study Day 1\n\n         18. Any skin breaks, irritation, or lesions present in the area to which the cream will\n             be applied, assessed at screening and check-in\n\n         19. A drug or food allergy which in the opinion of the Investigator contraindicates\n             participation in the study"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "62", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01986673", 
            "org_study_id": "SST-6006-001-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "5% Sildenafil Cream (SST-6006)", 
                "description": "5 % Sildenafil Cream", 
                "intervention_name": "5% Sildenafil Cream (SST-6006)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Oral Sildenafil 50 mg", 
                "description": "Oral Sildenafil 50 mg", 
                "intervention_name": "Oral Sildenafil 50 mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sildenafil"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Pharmacokinetic Characterization", 
        "lastchanged_date": "January 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Miami", 
                    "country": "United States", 
                    "state": "Florida"
                }, 
                "name": "SST Clinical Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Cmax, Tmax, AUC 0-tlast, AUC 0-t, Kel, AUC0-inf, t1/2, CL/F", 
            "safety_issue": "No", 
            "time_frame": "32 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01986673"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of subjects experiencing TEAEs.", 
                "measure": "Adverse Events", 
                "safety_issue": "No", 
                "time_frame": "7 to 10 days"
            }, 
            {
                "description": "Changes from baseline in clinical chemistry values", 
                "measure": "Clinical Chemistry Tests", 
                "safety_issue": "No", 
                "time_frame": "1 day"
            }, 
            {
                "description": "Vital sign changes from pre-dose", 
                "measure": "Vital Signs", 
                "safety_issue": "No", 
                "time_frame": "1 day"
            }
        ], 
        "source": "Strategic Science & Technologies, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Strategic Science & Technologies, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}